Their primary applications are in managing type 2 diabetes and obesity due to their effects on insulin secretion, glucagon suppression, and appetite
However, on July 2324, 2026, the FDAs Pharmacy Compounding Advisory Committee (PCAC) voted on inclusion of three of KLOWs peptide compounds for the 503A Bulks List: BPC-157 : 86 voted in favor of inclusion, with one abstention TB-500 : 86 voted in favor of inclusion, with one abstention KPV : 86 voted in favor of inclusion, with one abstention Note: TB-500 is a fragment of the full-length thymosin beta-4 (43 amino acids)
TB-500 is also administered via subcutaneous injection, but the schedule is different: one or two injections per week rather than daily
Vitals check
Look for HPLC or LC-MS purity of at least 98%, confirmed molecular weight matching TB-500 (approximately 4963 Da), endotoxin testing (LAL assay), and residual solvent panels
Start your free assessment now